# ADRX catalysts: ADARx Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/adrx/catalysts

> ADARx Pharmaceuticals, Inc. (ADRX) has 13 upcoming catalysts. The next is the agazisiran interim data readout, 2H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ADRX?

ADARx Pharmaceuticals, Inc. (ADRX) has 13 upcoming catalysts. The next is the agazisiran interim data readout, 2H 2027. SEC prospectus (424B): "The Phase 2 clinical trials are enrolling, with initial data in IgAN, C3G and PNH expected in mid- to second half of 2027." [Calendar and source filings](https://sec-api.dev/companies/adrx/catalysts)

Source: SEC prospectus (424B), accession 0001193125-26-403094, https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm (retrieved 2026-11-12). Last confirmed 2026-09-28. Cite: https://sec-api.dev/companies/adrx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | ADARx Pharmaceuticals, Inc. |
| Ticker | ADRX (Nasdaq) |
| SEC CIK | 1802369 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/adrx |

## Cash runway

Cash $901.0M as of 2026-09-30; quarterly burn $25.7M; about 105.3 months of runway at that rate (XBRL company facts, accession 0001193125-26-458444).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2024 | [Onvuzosiran trial start](https://sec-api.dev/pdufa/onvuzosiran) | ADRX |  | completed | "In January 2024, we initiated our Phase 2a clinical trial of SC doses of onvuzosiran in patients with HAE." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)) |
| Aug 2025 | [ADX-626 trial start](https://sec-api.dev/pdufa/adx-626) | ADRX |  | completed | "In August 2025, we initiated a Phase 1, randomized, blinded clinical trial of ascending doses of ADX-626 in healthy participants who are up to 45 years of age." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)) |
| Nov 2025 | [Agazisiran trial start](https://sec-api.dev/pdufa/agazisiran) | ADRX | GA secondary to AMD | completed | "In November 2025, we initiated a Phase 2 randomized, masked, placebo-controlled clinical trial of SC administered agazisiran in participants with GA secondary to AMD." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)) |
| Mar 2026 | [Agazisiran trial start](https://sec-api.dev/pdufa/agazisiran) | ADRX |  | completed | "In March 2026, we initiated a second Phase 2 clinical trial in China to evaluate the potential of agazisiran high dose as monotherapy and in combination with an" ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)) |
| November 12, 2026 | [ADARx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/adrx/catalysts) | ADRX |  | completed | "ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458321/adrx-ex99_1.htm)) |
| 2H 2027 | [Agazisiran interim data readout](https://sec-api.dev/pdufa/agazisiran) | ADRX |  | scheduled | "The Phase 2 clinical trials are enrolling, with initial data in IgAN, C3G and PNH expected in mid- to second half of 2027." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)) |
| late 2027 | [Onvuzosiran topline data readout](https://sec-api.dev/pdufa/onvuzosiran) | ADRX |  | scheduled | "STOP-HAE enrollment is ongoing, with topline data expected by the end of 2027." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)) |
| late 2027 | [ADX-199 trial start](https://sec-api.dev/pdufa/adx-199) | ADRX |  | scheduled | "We are advancing ADX-199 into IND-enabling studies and plan to initiate a Phase 1 clinical trial by the end of 2027 or in early 2028." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1802369/000119312526458444/adrx-20260930.htm)) |
| Nov 2027 to Feb 2028 | [Sirna topline data readout](https://sec-api.dev/pdufa/sirna) | ADRX | Hereditary Angioedema; HAE; Hereditary Angioedema - Type 1 | scheduled | "NCT06960213 (STOP-HAE: A Phase 3 Study of ADX-324 in HAE): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06960213)) |
| November 2027 | [Sirna primary completion](https://sec-api.dev/pdufa/sirna) | ADRX | Hereditary Angioedema; HAE; Hereditary Angioedema - Type 1 | scheduled | "NCT06960213 (STOP-HAE: A Phase 3 Study of ADX-324 in HAE): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-30 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06960213)) |
| Jul to Oct 2028 | [Adx-038 dose level 2 topline data readout](https://sec-api.dev/pdufa/adx-038) | ADRX | Immunoglobulin A Nephropathy (IgAN); Complement 3 Glomerulopathy (C3G); IC-MPGN | scheduled | "NCT07522099 (Chinese Adults With Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-10 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07522099)) |
| July 2028 | [Adx-038 dose level 2 primary completion](https://sec-api.dev/pdufa/adx-038) | ADRX | Immunoglobulin A Nephropathy (IgAN); Complement 3 Glomerulopathy (C3G); IC-MPGN | scheduled | "NCT07522099 (Chinese Adults With Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-10 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07522099)) |
| Dec 2028 to Mar 2029 | [Adx-038 dose level 2 topline data readout](https://sec-api.dev/pdufa/adx-038) | ADRX | IgAN; C3G; Complement-mediated Kidney Disease | scheduled | "NCT06989359 (Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989359)) |
| December 2028 | [Adx-038 dose level 2 primary completion](https://sec-api.dev/pdufa/adx-038) | ADRX | IgAN; C3G; Complement-mediated Kidney Disease | scheduled | "NCT06989359 (Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06989359)) |
| Feb to May 2030 | [Sirna topline data readout](https://sec-api.dev/pdufa/sirna) | ADRX | Geographic Atrophy Secondary to Age-related Macular Degeneration | scheduled | "NCT06990269 (Phase 2 Study of ADX-038 in Participants With Geographic Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02-28 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06990269)) |
| February 2030 | [Sirna primary completion](https://sec-api.dev/pdufa/sirna) | ADRX | Geographic Atrophy Secondary to Age-related Macular Degeneration | scheduled | "NCT06990269 (Phase 2 Study of ADX-038 in Participants With Geographic Atrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-02-28 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06990269)) |
| Jun to Sep 2030 | [Adx-324 dose level 1 topline data readout](https://sec-api.dev/pdufa/adx-324) | ADRX |  | scheduled | "NCT07428499 (Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07428499)) |
| June 2030 | [Adx-324 dose level 1 primary completion](https://sec-api.dev/pdufa/adx-324) | ADRX |  | scheduled | "NCT07428499 (Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-30 (ESTIMATED); Lead Sponsor ADARx Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07428499)) |

## Drugs

- [Adx-038 dose level 2](https://sec-api.dev/pdufa/adx-038): IgAN, Immunoglobulin A Nephropathy (IgAN)
- [ADX-199](https://sec-api.dev/pdufa/adx-199): 
- [Adx-324 dose level 1](https://sec-api.dev/pdufa/adx-324): Hereditary Angioedema (HAE)
- [ADX-626](https://sec-api.dev/pdufa/adx-626): 
- [Agazisiran](https://sec-api.dev/pdufa/agazisiran): ga secondary to amd
- [Onvuzosiran](https://sec-api.dev/pdufa/onvuzosiran): 
- [Sirna](https://sec-api.dev/pdufa/sirna): Geographic Atrophy Secondary to Age-related Macular Degeneration, Hereditary Angioedema

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/adrx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ADRX catalysts: ADARx Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/adrx/catalysts

```bibtex
@misc{secapidev_companies_adrx_catalysts_20261116,
  title        = {ADRX catalysts: ADARx Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/adrx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_adrx_catalysts_20261116","title":"ADRX catalysts: ADARx Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/adrx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
